GlassScriptPhysician profile
Paul Lapenna
NPI 1952711483
$2,594.90
in general payments reported to CMS, 2019-2025
35 companies · $74.41 in 2025
The $74.41 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $317 · 2021: $850 · 2022: $479 · 2023: $289 · 2024: $66.43 · 2025: $74.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $554.05 | 2019-2021 | |
| Abbvie INC. | $408.84 | 2021-2024 | |
| Sk Life Science, INC. | $222.81 | 2020-2023 | |
| Lundbeck LLC | $157.98 | 2019-2023 | Vyepti |
| Avanir Pharmaceuticals, INC. | $155.60 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $127.58 | 2019-2025 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $92.08 | 2021 | |
| Acadia Pharmaceuticals INC | $83.83 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $57.05 | 2021 | |
| Ucb, INC. | $54.61 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $50.39 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.25 | 2022 | |
| Aquestive Therapeutics, INC. | $42.62 | 2020 | |
| Amneal Pharmaceuticals LLC | $39.85 | 2019-2021 | |
| Banner Life Sciences, LLC | $38.09 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $36.87 | 2024 | |
| Amgen INC. | $35.88 | 2019-2023 | Aimovig |
| Medtronic, INC. | $34.12 | 2025 | Linq II |
| Lilly USA, LLC | $31.37 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $30.00 | 2023 | Nuedexta |
| Allergan, INC. | $26.85 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $25.92 | 2023 | Purified Cortrophin Gel |
| Csl Behring | $25.32 | 2022 | |
| Pfizer INC. | $22.78 | 2023 | |
| Livanova USA, INC. | $22.44 | 2019 | |
| Biogen, INC. | $20.54 | 2022 | |
| Genentech USA, INC. | $20.21 | 2025 | Ocrevus Zunovo |
| Arbor Pharmaceuticals, INC. | $18.33 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.90 | 2019 | |
| Akcea Therapeutics, INC. | $16.73 | 2019 | |
| Eisai INC. | $16.24 | 2021 | |
| Mdd US Operations, LLC | $15.54 | 2020 | |
| Grifols USA, LLC | $15.38 | 2020 | |
| Currax Pharmaceuticals LLC | $14.97 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lapenna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.